UroGen Pharma (URGN) EBT (2017 - 2026)

UroGen Pharma (URGN) has 10 years of EBT data on file, last reported at -$28.3 million in Q1 2026.

• Quarterly EBT rose 34.76% year-over-year to -$28.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$138.3 million (down 2.25% YoY) and the FY2025 annual result came in at -$153.4 million, down 23.68% from the prior year.
• EBT retreated to -$28.3 million in Q1 2026, from -$26.6 million in the prior quarter.
• In the past five years, EBT ranged from a high of -$21.9 million in Q3 2023 to a low of -$48.9 million in Q2 2025.
• A 5-year average of -$30.1 million and a median of -$28.2 million in 2022 frame the typical range for EBT.
• Annual changes were most pronounced in 2024 — EBT tumbled 57.31% — and 2026, when it surged 34.76%.
• Tracing URGN's EBT over 5 years: stood at -$28.2 million in 2022, then rose by 21.36% to -$22.2 million in 2023, then tumbled by 57.31% to -$34.9 million in 2024, then advanced by 23.59% to -$26.6 million in 2025, then decreased by 6.41% to -$28.3 million in 2026.
• The last three EBT figures came in at -$28.3 million (Q1 2026), -$26.6 million (Q4 2025), and -$34.4 million (Q3 2025), per Business Quant data.